Exhibit 03 · Caution / where the human data thins
Copper Peptide Side Effects in the Research Literature
Reported irritation and hyperpigmentation signals, the copper-toxicity question, the FDA status, and the incompatibilities — read with a buyer's skepticism and cited to source.
What the reported copper peptide side effects are
Copper Peptide Side Effects in the Research Literature are, for topical use, generally mild and localized — with two specific signals worth pinning to the board. Reported downsides include localized irritation and a hyperpigmentation signal with some topical applications, vitamin-C and low-pH-acid incompatibility that can destroy both actives, and low native skin bioavailability [16]. Broadly, the human clinical evidence is thin, much of it comes from a single research group, and there is no validated pharmacokinetic basis for systemic use.
This page reads the hazards the way the rest of the site reads the benefits: each one circled, sized honestly, and cited. None of it is a usage recommendation; it is a summary of what the record reports going wrong, and where it stays silent.
Reported irritation and hyperpigmentation signals
Localized hyperpigmentation has been reported with some topical copper-peptide applications — in one acne-scar microneedling study, on the order of 40% of subjects — and a CO2-laser post-procedure randomized trial (n=13) found no objective erythema benefit despite higher patient satisfaction [8]. The hyperpigmentation signal is the more notable of the two: it points to the copper-handling and delivery context (microneedling drives more peptide deeper) rather than to a systemic toxicity. The CO2-laser result is included precisely because it is null on the objective endpoint — honest counter-evidence belongs on a safety page [8].
Does GHK-Cu cause copper toxicity with repeated use?
No human copper-toxicity cases attributed to GHK-Cu appear in the peer-reviewed record. The GHK-Cu chelate has a very high copper stability constant (log K ~16.44) that mitigates the pro-oxidant risk of free copper; in vitro it completely blocked Cu2+-dependent LDL oxidation and reduced iron release from ferritin by 87% [7]. A theoretical copper-accumulation risk with prolonged systemic use is still flagged in the literature.
Copper accumulation and copper-zinc balance
The copper-toxicity question is best read as theoretical-but-flagged rather than observed. No human copper-toxicity cases attributed to GHK-Cu appear in the peer-reviewed record, and rodent studies used copper loads below the roughly 35 mg/kg ion-toxicity threshold. The chemistry argues against the hazard for the bound complex: log K ~16.4 binding, full blockade of copper-dependent LDL oxidation in vitro, and an 87% reduction in ferritin iron release [7].
The residual concern is specific and worth stating plainly: prolonged systemic use raises a theoretical copper-accumulation and copper-zinc-balance question that the literature flags but has not resolved in humans, because no validated systemic pharmacokinetic data exist. These are copper toxicity concerns read at their true size — real enough to name, not demonstrated to occur.
Is GHK-Cu FDA approved?
No. There is no FDA-approved GHK-Cu drug product for any indication. Topical Copper Tripeptide-1 is a legal cosmetic ingredient in the US, EU, and UK, but injectable, oral, or other systemic formulations are unapproved research chemicals with no established regulatory pathway.
What are the downsides of copper peptides?
Reported downsides include localized irritation and a hyperpigmentation signal with some topical applications, vitamin-C and low-pH-acid incompatibility that can destroy both actives, and low native skin bioavailability [16]. Broadly, human clinical evidence is thin, much of it comes from a single research group, and there is no validated pharmacokinetic basis for systemic use.
The single-investigator caveat
A large share of the foundational GHK-Cu mechanistic and review literature originates from one investigator, Loren Pickart (1938-2023), and close colleagues. That does not make the work wrong — the picomolar collagen dose-response has independent corroboration, and the gene-expression analyses draw on the public Connectivity Map [1][2]. But independent replication of the broader gene-modulation and anti-aging claims is limited, and a careful reader weights a single-source claim differently from a multi-lab one.
This is the reason the "~4,000 genes" figure is struck through across this site and corrected to the ~2,100 genes the >=50%-change threshold table actually reports [2]. The most-repeated copper-peptide statistic is an extrapolation of a single-group analysis — exactly the kind of figure a safety reading should circle and re-check rather than pass along.
The systemic pharmacokinetics gap
The largest single gap is systemic pharmacokinetics. No validated human half-life, Cmax, bioavailability, or tissue-distribution data exist for injectable or systemic GHK-Cu, and community dosing protocols have no peer-reviewed basis. The free tripeptide is rapidly cleared by plasma peptidases — a rat study documented rapid metabolism of GHK to the dipeptide HK after IV dosing — and secondary literature cites a short systemic elimination half-life on the order of 1-2 hours, with the copper chelate more stable than free GHK [16].
Topical use sidesteps much of this by forming a local dermal depot (about 97 ug/cm^2 over 48 hours) rather than relying on systemic circulation [5]. For any non-topical route, the correct statement is that the human PK is simply unknown, which is the honest gap this page exists to mark.